Breaking Through the Bitterness Bottleneck

From highly water-soluble APIs to the strict constraints of personalized therapies, masking unpleasant drug tastes remains a complex engineering challenge, requiring forward-thinking downstream strategies.

Oral drug products have helped improve the lives of many patients, offering treatment in a convenient and easy to manage way; however, if the finished drug is unpalatable, patients can be reluctant to adhere to treatment and their symptoms or condition can worsen. Given the fact that most active ingredients have an unpleasant or bitter taste, the pharmaceutical industry has been required to adopt approaches that can mask the flavor and improve the overall experience for the patient without negatively impacting the therapeutic effect of the drug.

There is a direct and strong link between palatability of a drug and the tolerability of whether or not a patient can take the drug, particularly in certain patient populations, emphasizes Nathan H. Dormer, Ph.D., Senior Director, Drug Product Development at Adare Pharma Solutions. “Patient-centric formulations have been associated with dramatic adherence improvements among children and older adults. Older patients often report skipping or delaying doses because of difficulty swallowing, of which taste can be a factor,” he says.

“When a dose is hard to take, patients defer it, halve it, or abandon the therapy, and a drug that is not taken cannot work regardless of its intrinsic efficacy,” Dormer stresses. “Off-label crushing introduces a further risk, since it can disrupt controlled-release mechanisms and dosing accuracy. Palatability and swallowability ultimately determine whether a therapy is taken as prescribed and therefore whether it can deliver its intended clinical benefit.”

Technical Bottlenecks

While many strategies have matured over the years, achieving robust and effective taste-masking for modern therapies remains technically challenging. “Several factors make taste-masking difficult even as the toolkit has matured,” confirms Dormer.

“Bitterness tracks closely with aqueous solubility, so highly water-soluble APIs remain hard to mask without altering release. Low potency can exacerbate the problem, since high-dose molecules leave little room for coating relative to the drug load,” Dormer remarks. “Newer therapies often arrive as potent but poorly soluble or highly bitter compounds that resist conventional excipients.”

Additionally, physical particle attributes can dictate the success of taste-masking, particularly when employing polymer coating to mask taste, Dormer continues. “API and/or substrate particle size, shape, and surface area all govern how much physical coating or matrix is required for sufficient taste-masking, and non-uniform particles of any composition coat unevenly, which adversely affects the end goal,” he says.

The increasing prominence on personalized therapies is also posing challenges to the development of palatable drugs, Dormer explains. “Personalized medicine pushes formulation toward smaller, more varied batches and a wider range of dose strengths, and this changes what taste-masking has to accommodate,” he confirms. “The constant is that taste-masking still must hold across each strength without shifting the release profile, so process robustness across scale matters more than ever.”

For these therapies, uniform particle technologies are particularly useful as “consistent coating behaves the same whether the batch is large or small, and platforms that produce taste-masked and dose-titratable powder can be compounded into several final formats from a single intermediate,” Dormer adds. “Format flexibility becomes the practical requirement: one taste masked particle that can move into a powder, a dry syrup, an orally disintegrating tablet, or a soft-textured form depending on the patient.”

Alternative approaches to improving the palatability of drugs, such as the use of bitter blockers, are promising, but further work is required before these approaches can become more mainstream, Dormer notes. “Bitterness antagonists remain an active research area, but the science is not yet mature enough for routine commercial formulation use,” he says. “The work stays case-specific rather than templated.”

Balancing Acceptability with Performance

A robust taste-masking strategy cannot be designed or evaluated in isolation from its immediate effects on critical quality attributes (CQAs) such as dissolution kinetics, solubility, and overall bioavailability, Dormer confirms. “Any coating, thickening agent, or complexation step warrants a risk assessment in regard to overall bioavailability before it advances,” he says. “The only correct discipline is to treat acceptability and biopharmaceutical performance as parts of one design exercise rather than sequential goals.”

In practice, formulators must select specific excipients and precise coating weights against a defined, non-negotiable in vivo release target, ensuring that the physical barrier remains completely intact within the oral cavity but dissolves immediately and predictably once it reaches the target absorption window in the gastrointestinal tract, Dormer specifies. “Uniform particles help here, since consistent coating thickness yields predictable release and reduces dose-to-dose variability,” he says.

“Ranking tools such as customized dissolution methods, electronic tongue, and Brief Access Taste Aversion (BATA) models support formulation selection, though none are fully predictive,” Dormer reveals. “The aim is a barrier strong enough to mask taste while thin enough to preserve potency, stability, and therapeutic performance, which is are the primary and uncompromising goals.”

Navigating Regulatory Shifts

Beyond the bench-level technicalities, the regulatory environment is leading to a fundamental rethink of how drug developers approach palatability. According to Dormer, modern global health authorities are expecting patient-centricity to be integrated from the start of development rather than applied as a late-stage corrective measure.

“One point worth adding is that taste-masking is increasingly a regulatory expectation rather than a differentiator,” Dormer summarizes. “Acceptability now sits alongside safety and efficacy in development, and authorities expect patient-centricity to be built into the dosage form rather than addressed after the fact. That raises the bar on the documentation and analytical work behind a masking claim.”

This evolving landscape ultimately penalizes developers who defer palatability strategies until phase III or scale-up. As taste coatings and matrix adjustments intrinsically interact with foundational parameters, such as core solubility and solid-state stability, addressing them early protects the asset from late-stage re-formulation crises, Dormer asserts.

“Working with a partner that keeps formulation and manufacturing under one roof shortens that loop, because the same team can weigh how a coating choice plays out at commercial scale,” Dormer concludes. “The throughline is straightforward: the formulation only succeeds if the patient is willing and able to take it.”

About the Contributor

Nathan H. Dormer, Ph.D., is Senior Director, Drug Product Development at Adare Pharma Solutions. In his role, Nathan is responsible for pharmaceutical development activities at Adare’s facilities, supporting a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Nathan earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.

Image Credit: © tostphoto - stock.adobe.com